TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Processa Pharmaceuticals ( (PCSA) ) has provided an update.
On June 30, 2025, Processa Pharmaceuticals held its Annual Shareholder Meeting in Hanover, MD, but adjourned without conducting business due to a lack of quorum. The meeting is rescheduled for July 30, 2025, with the same record date, allowing only stockholders of record as of May 1, 2025, to vote.
The most recent analyst rating on (PCSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing drugs to address unmet medical needs.
Average Trading Volume: 17,897,603
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.14M
For detailed information about PCSA stock, go to TipRanks’ Stock Analysis page.